Alector Reports Steep Revenue Decline and Widened Net Loss for Q4 and Full Year 2025
Summary
Alector reported a substantial year-over-year decline in collaboration revenue and a significantly widened net loss for Q4 and full year 2025, despite maintaining a cash runway through 2027.
Key Events
-
Collaboration Revenue Plummets
Collaboration revenue for the full year 2025 drastically decreased to $21.0 million from $100.6 million in 2024, primarily due to the satisfaction of performance obligations related to the AL002 program and the latozinemab FTD-C9orf72 Phase 2 trial in late 2024.
-
Net Loss Significantly Widens
The company reported a net loss of $142.9 million for the full year 2025, a substantial increase from a net loss of $119.0 million in 2024. The fourth quarter net loss also widened significantly to $37.3 million from $2.1 million in the prior year.
-
Reduced Operating Expenses
Research and development expenses decreased to $123.1 million for the full year 2025 from $185.9 million in 2024, and general and administrative expenses also declined, largely due to workforce reductions.
-
Cash Runway Through 2027
Alector ended 2025 with $256.0 million in cash, cash equivalents, and investments, which management expects will fund operations at least through 2027.
Analysis
Alector, Inc. announced significantly weaker financial results for the fourth quarter and full year 2025, marked by a drastic reduction in collaboration revenue and a substantial increase in net loss. This financial deterioration follows the trends highlighted in the concurrently filed 10-K, which noted increased net losses, a drastic drop in collaboration revenue due to multiple clinical trial failures, and extensive workforce reductions. While the company maintains a cash runway through 2027, the sharp decline in revenue and widening losses indicate significant operational challenges. Investors should monitor the upcoming interim futility analysis for the PROGRESS-AD Phase 2 trial and the presentation of INFRONT-3 Phase 3 trial results, as these clinical milestones are critical for future prospects.
At the time of this filing, ALEC was trading at $2.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $260.9M. The 52-week trading range was $0.87 to $3.40. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.